TGF-β induces matrisome pathological alterations and EMT in patient-derived prostate cancer tumoroids

Matrix Biol. 2024 Jan:125:12-30. doi: 10.1016/j.matbio.2023.11.001. Epub 2023 Nov 8.

Abstract

Extracellular matrix (ECM) tumorigenic alterations resulting in high matrix deposition and stiffening are hallmarks of adenocarcinomas and are collectively defined as desmoplasia. Here, we thoroughly analysed primary prostate cancer tissues obtained from numerous patients undergoing radical prostatectomy to highlight reproducible structural changes in the ECM leading to the loss of the glandular architecture. Starting from patient cells, we established prostate cancer tumoroids (PCTs) and demonstrated they require TGF-β signalling pathway activity to preserve phenotypical and structural similarities with the tissue of origin. By modulating TGF-β signalling pathway in PCTs, we unveiled its role in ECM accumulation and remodelling in prostate cancer. We also found that TGF-β-induced ECM remodelling is responsible for the initiation of prostate cell epithelial-to-mesenchymal transition (EMT) and the acquisition of a migratory, invasive phenotype. Our findings highlight the cooperative role of TGF-β signalling and ECM desmoplasia in prompting prostate cell EMT and promoting tumour progression and dissemination.

Keywords: Cancer; Epithelial-to-mesenchymal transition (EMT); Extracellular matrix (ECM); Prostate; Transforming growth factor (TGF)-β; Tumoroids; Tumour.

MeSH terms

  • Cell Line, Tumor
  • Epithelial-Mesenchymal Transition
  • Extracellular Matrix / metabolism
  • Humans
  • Male
  • Prostate / metabolism
  • Prostatic Neoplasms* / pathology
  • Transforming Growth Factor beta* / metabolism

Substances

  • Transforming Growth Factor beta